The company has launched Testosterone Topical Solution, 30 mg per actuation, in the US after receiving approval from the United States Food and Drug Administration (USFDA), Lupin said in a filing to BSE.
The company's product is the generic version of Eli Lilly and the companys Axiron topical solution, 30 mg per actuation, it added.
As per IQVIA MAT December 2017 data, testosterone topical solution, 30 mg per actuation had annual sales of approximately USD 179 million in the US, it added.
Shares of Lupin today closed at Rs 821.30 per scrip on BSE, up 1.75 per cent from the previous close.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)